Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | NA |
| Strategy: | NA |
| Study Type: | Phase I |
| Species: | Human |
| Stage: | In progress |
| Study Start Date: | NA |
| Study Made Public: | NA |
Title
A Phase 1 study to evaluate the safety and immunogenicity of eOD-GT8 60mer mRNA vaccine (mRNA-1644) in HIV-1 uninfected adults in good general health
Description
CAVD 546 (IAVI G003) is a Phase I clinical trial to evaluate eOD-GT8 60mer mRNA vaccine for detectable VRC01-class IgG B-cells in African populations.
Sign in to see full information about this study and to download study data.
Products
eOD-GT8 60mer mRNAIntegrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.